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Understanding rheumatic diseases from the perspective of chemokine biology has shaped
and will continue to shape our approach for targeted drug design. Among different kinds
of chemokines, fractalkine/CX3CL1 has been found to play an important role in inﬂamma-
tion, portraying unique functional, and structural characteristics. This review summarizes
the emerging role of fractalkine/CX3CL1 from a functional and clinical perspective and pro-
vides evidence to validate it as a potential therapeutic target in rheumatic diseases such as
rheumatoid arthritis, Sjögren’s syndrome, systemic lupus erythematosus, scleroderma, as
well as diseases related to vascular inﬂammation. From this, recent studies investigating
potential therapeutic agents against fractalkine/CX3CL1’s role in pathology have shown
promise.
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INFLAMMATION AND CHEMOKINES
Chemokines are small molecular weight heparin-binding pro-
teins that play important roles in the recruitment and retention
of inﬂammatory cells at the site of inﬂammation or injury by
their chemotactic activity. Since their initial discovery, chemokines
have been found to play a crucial role in directing mononuclear
cells, adaptive immunity, and disease pathogenesis (Charo and
Ransohoff, 2006). Chemokines elicit their impact through the
chemokine receptors, the G protein-coupled class of receptors,
which upon stimulation transduce an intracellular signal, and may
cause additional changes within the cell and promote inﬂam-
mation (Charo and Ransohoff, 2006). Fundamentally, mature
chemokines are secreted and processed at the NH2 terminus,
rarely at the COOH-terminus or at internal sites, to yield trun-
cated forms with various levels of biological activity (Baggiolini
et al., 1994). This cleavage at the NH2-terminal sequence preced-
ing the ﬁrst cysteine ampliﬁes their biological activity, with little to
no reported effect of the processing at the COOH-terminal amino
acids (Baggiolini et al., 1994).
FRACTALKINE/CX3CL1
A study by Bazan et al. (1997) reported the discovery of a
unique chemokine subclass, CX3C, which was different in terms
of structure, biochemical features, tissue distribution, and chro-
mosomal localization from known chemokines and represented
by only one member, referred to as fractalkine or CX3CL1.
Synthesized as a transmembrane molecule, fractalkine/CX3CL1,
consists of an extracellular NH2-terminal domain, a mucin-like
stalk, a transmembrane α helix, and a short cytoplasmic tail
(Bazan et al., 1997). It was found to exist as a soluble form
(consisting only of the extracellular domain and mucin-like
stalk) and a membrane-bound form, which gave it an advan-
tage to function both as a chemoattractant and an adhesion
molecule as well. Soluble fractalkine/CX3CL1 is generated by
the limited proteolysis of a disintegrin and metallopeptidase
10 (ADAM10) and ADAM17/tumor necrosis factor-α-converting
enzyme (ADAM17/TACE) and acts as a chemoattractant for
monocytes, natural killer (NK) cells, and T cells. Further mecha-
nistic studies on the proteolytic shedding of fractalkine/CX3CL1
suggest the role of ADAM10 in the constitutive shedding and
of ADAM17 in response to cell activation. Interestingly, a recent
study found thatADAM17 is less responsible for constitutive shed-
ding of fractalkine/CX3CL1 in HepG2 cells and suggested that
ADAM10mayplay a greater role in this process (Hundhausen et al.,
2003; Turner et al., 2010). Membrane-bound fractalkine/CX3CL1,
which supports integrin-independent leukocyte adhesion, can be
induced on primary endothelial cells by inﬂammatory cytokines
(Garcia et al., 2000).
CELLULAR DISTRIBUTION AND EXPRESSION
CD4+ helper cells (Th) and CD8+ cytotoxic T cells (Tc) are
divided into two distinct groups based on the cytokines they
produce. Th1 and Tc1 cells secrete IFN-γ, tumor necrosis factor-
α (TNF-α), and IL-2, which mediate immune responses against
intracellular pathogens and are associated with pathological
processes such as organ-speciﬁc autoimmune diseases. Th2 and
Tc2 cells produce IL-4, IL-5, and IL-13, which mediate immune
responses against extracellular pathogens and are associated with
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allergic immune responses (Umehara et al., 2004). Recent stud-
ies have shown that various lymphocyte subsets with different
tissue tropisms and functions express speciﬁc chemokine recep-
tors. The majority of CX3CR1-expressing CD4+ and CD8+ T cells
also express CCR5, but not CXCR3, which suggests that CX3CR1-
expressing T cells partially overlap Th1 and Tc1 cells, respectively
(Nishimura et al., 2002). CX3CR1 has also been found to have
preferential expression in Th1 cells compared to Th2 cells, with
only Th1 cells responding to fractalkine/CX3CL1 (Fraticelli et al.,
2001). CX3CR1-expressing cells include CD4+, CD8+ T cells, γδ
cells, and NK cells, and they also express CD57 and CD11b, which
are good markers for cytotoxic lymphocytes, but rarely express
CD27, CD28, and CD62L. Most CX3CR1-expressing cells have
cytoplasmic granules which contain perforin and granzyme B
(Nishimura et al., 2002).
Apart from expression in the endothelia, fractalkine/CX3CL1
and CX3CR1 are strongly expressed in the central nervous system.
Fractalkine/CX3CL1 is one of the most expressed chemokines
in the brain, which may help to explain its role in neuropathic
pain. In the CNS, neurons express fractalkine/CX3CL1 while
astrocytes express CX3CR1 (Marchesi et al., 2010). From this,
fractalkine/CX3CL1plays a role in tumordevelopment in theCNS,
where it may be induced by TNF-α or TGF-β in neurons and aid
in the aggregation of glioblastomas (Sciume et al., 2010).
The expression of fractalkine/CX3CL1 in monocytes from
rheumatoid arthritis (RA) peripheral blood and synovial ﬂuid (SF)
validates an important role of this chemokine in immune-related
inﬂammatory diseases. Fractalkine/CX3CL1 is also expressed in
macrophages, ﬁbroblasts, endothelial, and dendritic cells in RA
synovial tissue (ST; Ruth et al., 2001). CCL26 has recently been
found to be an agonist for CX3CR1, from which it may play a dual
role in allergic diseases such as atopic dermatitis and psoriasis
(Nakayama et al., 2010).
UNIQUE MECHANISM OF CHEMOTAXIS BY FRACTALKINE/CX3CL1
Before fractalkine/CX3CL1 was discovered, the mechanism of
chemotaxis was thought to begin with the association of solu-
ble chemokines with cell surface proteoglycans and tissue matrix
components, followed by the interaction between chemokines and
their speciﬁc receptors on leukocytes, eventually resulting in the
activation of the members of the integrin family of adhesion mol-
ecules through a G-coupled protein receptor mechanism (Tanaka
et al., 1993). However, fractalkine/CX3CL1 mediates the mecha-
nism for leukocyte adhesion in a unique fashion. The chemokine
domain is presented at the top of the membrane-bound, mucin-
like stalk, where it acts as an adhesion molecule making the associ-
ation with proteoglycans and other adhesion molecules unnec-
essary. Interaction between fractalkine/CX3CL1 and CX3CR1
can markedly enhance integrin afﬁnity, which further facilitates
extravasation of leukocytes during the initial tethering and trans-
migration steps (Jones et al., 2010). Fractalkine/CX3CL1 expres-
sion on inﬂamed endothelium along with the coexpression of
intercellular adhesion molecule (ICAM)-1 and vascular cell adhe-
sion molecule (VCAM)-1, greatly enhances cell adhesion func-
tion by capturing CX3CR1-expressing cells from the blood and
promoting migration into tissue (Umehara et al., 2004). Stud-
ies have suggested that fractalkine/CX3CL1 expression at the site
of inﬂammation can attract and activate NK cells, resulting in
the consequent lysis of neighboring endothelial cells (Yoneda
et al., 2000; Umehara et al., 2001). Increased fractalkine/CX3CL1,
ICAM-1, and VCAM-1 expression on endothelial cell mem-
branes can result from certain conditions such as viruses/bacteria,
ischemia, or cytokine induction (IL-1, TNF-α, IL-6; Lanier et al.,
1997). The resulting expression of adhesion molecules and
fractalkine/CX3CL1 increases the adhesion and transmigration of
NK cells between endothelial cells, causing inﬂammation.
INDUCERS OF FRACTALKINE/CX3CL1
There are several known inducers of fractalkine/CX3CL1 that pro-
mote pathology in a variety of diseases. These inducers include
proinﬂammatory cytokines such as TNF-α, IFN-γ, IL-1β, but also
lipopolysaccharide (LPS; Garcia et al., 2000; Yoshida et al., 2001;
Schroder et al., 2004; Matsumiya et al., 2010), providing a possible
link between fractalkine/CX3CL1 and rheumatic diseases.
TUMOR NECROSIS FACTOR-α
Tumor necrosis factor-α is a pleiotropic cytokine that exerts
potent proinﬂammatory effects and is implicated in athero-
sclerosis and other metabolic and inﬂammatory disorders such
as obesity and RA. TNF-α was originally found to upregu-
late fractalkine/CX3CL1 in brain inﬂammation and subsequently
was termed “neurotactin” until later being designated fractalkine
(Okamoto et al., 1997). Recent studies have shown that TNF-α sig-
niﬁcantly increases fractalkine/CX3CL1 expression (Garcia et al.,
2000;Moon et al., 2006).A study byMoon et al. (2006) showed that
fractalkine/CX3CL1 mRNA expression was signiﬁcantly increased
by TNF-α stimulation in human umbilical vein endothelial cells
(HUVECs). Evaluation of signaling pathways suggested that TNF-
α induced fractalkine/CX3CL1 expression is mediated primarily
through the expression of NF-κB, a highly regulated transcription
factor involved in inﬂammatory responses (Brasier, 2006; Moon
et al., 2006). This notion was further supported by another study
in which fractalkine/CX3CL1 induction by TNF-α in rat aortic
endothelial cells was suppressed through the blockade of NF-κB
(Garcia et al., 2000).
INTERFERON-γ
Interferon-γ mediates a wide variety of immunological func-
tions, including upregulation of pathogen recognition, antigen
processing and presentation, viral defense, inhibition of cellular
proliferation and effects on apoptosis, activation of microbicidal
effector functions, immunomodulation, and leukocyte trafﬁcking
(Schroder et al., 2004). TNF-α and IFN-γ both serve as agonists
for the induction of a variety of cytokines, while synergism of
TNF-α and IFN-γ leads to superinduction in certain types of
cytokines (Paludan, 2000). One study reports that treatment of
HUVECs with a combination of IFN-γ or TNF-α synergistically
induced fractalkine/CX3CL1 expression (Matsumiya et al., 2010).
Costimulation with TNF-α and IFN-γ is also known to induce
fractalkine/CX3CL1 expression by more than 10-fold in astro-
cytes (Yoshida et al., 2001). In RA synovial ﬁbroblasts, synergistic
induction with TNF-α and IFN-γ enhances fractalkine/CX3CL1
expression more than either cytokine alone (Volin et al., 2007).
These studies propose fractalkine/CX3CL1 regulation through the
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post-transcriptional mechanism mediated by the p38 mitogen
activated protein kinase (MAPK) mechanism, then HuR (RNA
binding protein) shuttling from the nucleus to the cytoplasm,
where it stabilizes mRNA and helps regulate gene expression
(Hasegawa et al., 2009; Matsumiya et al., 2010).
INTERLEUKIN-1β
Interleukin-1β is secreted systemically from blood monocytes, tis-
sue macrophages, dendritic cells, B lymphocytes, and NK cells.
IL-1β has been shown to induce fractalkine/CX3CL1 expression
in some studies. Garcia et al. (2000) reported NF-κB dependent
fractalkine/CX3CL1 induction by IL-1β in rat aortic endothelial
cells. In a parallel study by Denes et al. (2008), the lack of CX3CR1
signiﬁcantly reduced IL-1β and TNF-α expression, which resulted
in decreased leukocyte inﬁltration in CX3CR1−/− animals and
consequent ischemicdamage and inﬂammation in the cerebrum in
mice. Inhibiting IL-1β expression may cause a decrease in inﬂam-
matory chemokine expression, which provides one possible way
to control fractalkine/CX3CL1 synthesis.
PATHOLOGICAL ROLE OF FRACTALKINE/CX3CL1 IN
RHEUMATIC DISEASES
RHEUMATOID ARTHRITIS
Rheumatoid arthritis is the most common form of inﬂammatory
arthritis in which the recruitment and retention of monocytes and
T lymphocytes into joints is an integral pathological phenome-
non (Pope, 2002). Edema, synovial hyperplasia, and destruction
of cartilage and bone in RA is caused by the inﬁltration of inﬂam-
matory cells such as macrophages, B cells, T cells, and dendritic
cells into the joint (Iwamoto et al., 2008). Leukocyte inﬁltration
into the synovium is regulated through a multi-step process that
involves interactions between leukocytes and endothelial cells, cel-
lular adhesion molecules, and chemokines and their receptors
(Iwamoto et al., 2008). Proinﬂammatory cytokines such as 1L-
1β, TNF-α, and IFN-γ not only start a vicious cycle of synovial
inﬂammation, but also produce chemokines that further stim-
ulate different cell types in the affected joint including synovial
ﬁbroblasts and chondrocytes to release inﬂammatory mediators
and matrix metalloproteinases (MMPs), to cause pathological
remodeling, leading to joint destruction (Sawai et al., 2007).
Playing a unique role in RA, fractalkine/CX3CL1 acts as
a chemotactic agent for monocytes and lymphocytes and
as a cellular adhesion molecule (Koch, 2005). By attracting
macrophages that express the CX3CR1 receptor within RA syn-
ovium, fractalkine/CX3CL1 plays an important role in the devel-
opment of RA as shown in Figure 1. The study by Ruth et al.
(2001) found high levels of soluble fractalkine/CX3CL1 in RA
SF. Analysis of the cell-speciﬁc expression in peripheral blood
and SF in this study show that primarily monocytes expressed
fractalkine/CX3CL1, while macrophages, ﬁbroblasts, endothelial,
and dendritic cells expressed this chemokine in ST. In terms of
pathological relevance, these levels in RA SF were signiﬁcantly
elevated compared with SF from osteoarthritis (OA) patients
suggesting a more aggressive role of fractalkine/CX3CL1 in RA
pathogenesis (Ruth et al., 2001). Some parallel studies also showed
that the surface expression of CX3CR1 on CD8+ T cells from
RA patients was roughly three fold when compared to the cells
derived from the healthy subjects (Nanki et al., 2002). In addition
to RA, fractalkine/CX3CL1 can induce chemotaxis in osteoarthri-
tis (OA) ﬁbroblasts, which may indicate a novel role in regu-
lating OA ﬁbroblast migration to bone fragments, contributing
to synovitis (Klosowska et al., 2009). Administration of anti-
fractalkine/CX3CL1 monoclonal antibody to mice signiﬁcantly
reduced the incidence of arthritis and tissue destructive trafﬁcking
of monocytes to the synovium (Nanki et al., 2002, 2004).
Detrimental tissue remodeling in RA is supported by neo-
vascularization and an angiogenic microenvironment that plays
an important role in chronic inﬂammation in RA. Some proin-
ﬂammatory cytokines may directly stimulate angiogenesis or act
indirectly by enhancing the production of angiogenic chemokines.
To investigate the mediatory role of fractalkine/CX3CL1 in
this process, one study showed that RA SF depleted of
fractalkine/CX3CL1 exhibits a lower angiogenic effect as com-
pared to control SF (Volin et al., 2001). Because of signiﬁcant
expression in RA, there is subsequently an increased cardiovas-
cular risk that may contribute to the mortality of RA patients
through enhanced systemic inﬂammation (Ruth et al., 2001; Volin
et al., 2001).
Fractalkine/CX3CL1 plays a role in an uncommon but severe
complication of RA, rheumatoid vasculitis (RV) which causes
skin and eye disorders, neuropathy, and systemic inﬂamma-
tion (Genta et al., 2006). In patients suffering from RV, sol-
uble fractalkine/CX3CL1 is signiﬁcantly expressed and its lev-
els correlated with the severity of vasculitis (Matsunawa et al.,
2006). Patients receiving treatment for RV with glucocorticoids,
methotrexate, or inﬂiximab expressed signiﬁcantly diminished
soluble fractalkine/CX3CL1 levels in serum samples (Matsunawa
et al., 2006). These therapies may target fractalkine/CX3CL1 pro-
duction in various ways to help regulate the progression of RV in
patients with RA.
SJÖGREN’S SYNDROME
Sjögren’s syndrome (SS) is a systemic autoimmune disease in
which immune cells attack and destroy the exocrine glands that
produce tears and saliva (Delaleu and Jonsson, 2008). SS symp-
toms include dry eyes (xerophthalmia) and dry mouth (xerosto-
mia; Kruszka and O’Brian, 2009). SS occurs in two basic forms:
(1) primary SS, which is a solitary process and is not associated
with any other illness, and (2) secondary SS, in which the disease
develops in the presence of another autoimmune disease such as
RA (Kruszka and O’Brian, 2009; Ramos-Casals et al., 2010). SS
represents a complex, multifaceted activation of the immune sys-
tem in which lymphocyte dysregulation and hyperactivity play a
major role in the disease (Kruszka and O’Brian, 2009).
A study by Wildenberg et al. (2008) provides evidence that
fractalkine/CX3CL1 cleavage is enhanced in SS, which may con-
tribute to the increased chemotaxis. Interestingly, this study found
an organ-speciﬁc fractalkine/CX3CL1 cleavage, with a 17-kDa
fragment in the salivary glands of non-obese diabetic (NOD)
mice. This phenomenon was observed as early as 10weeks of
age, where the animals were probably in a pre-disease or sub-
clinical stage of SS, and existed until 20weeks of age, where the
disease may have advanced to overt stage. Surprisingly, the pro-
tease responsible for this cleavage has not been identiﬁed and
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FIGURE 1 | Role of fractalkine/CX3CL1 in the development of RA.
A schematic representation of a normal knee and an RA knee. Inﬁltration of
leukocytes results in edema and synovial hyperplasia and consequent
destruction of cartilage and bone (Iwamoto et al., 2008). When
fractalkine/CX3CL1 is present, the chemokine domain is presented at the top
of the membrane-bound mucin-like stalk, where it acts as an adhesion
molecule (Umehara et al., 2004). Immobilized fractalkine/CX3CL1 exhibits
rapid and high afﬁnity binding to CX3CR1, which consequently increases
integrin afﬁnity and leukocyte adhesion (Jones et al., 2010). Soluble
fractalkine/CX3C1 binds to CX3CR1 aiding leukocyte extravasation through
the vascular wall and into the tissue, further initiating the inﬂammatory
response (Umehara et al., 2004). Membrane-bound fractalkine/CX3CL1 is
cleaved by ADAM10 and ADAM17/TACE to generate soluble
fractalkine/CX3CL1, which consists of the chemokine domain and the
mucin-like stalk (Bazan et al., 1997;Garton et al., 2001;Hundhausen et al.,
2003, 2007).
appears to not involve ADAM10 or ADAM17/TACE. The authors
propose that fractalkine/CX3CL1 is potentially a new autoanti-
gen in SS (Wildenberg et al., 2008). In another study by Tsub-
ota et al., fractalkine/CX3CL1 expression was upregulated in SS
affected mice. Furthermore, lacrimal and salivary gland-speciﬁc
fractalkine/CX3CL1 transgenic mice showed the expression of
fragmented fractalkine/CX3CL1 and lymphocytic inﬁltration in
their lacrimal glands (Tsubota et al., 2009). In SS patients, serum
samples exhibit elevated fractalkine/CX3CL1, ∼1.8-fold higher
than RA patients and∼3.6-fold higher than healthy patients (Sato
et al., 2006). These results suggest that fractalkine/CX3CL1 not
only plays an important role in the progression of SS, but also may
beprocesseddifferently in variousorgans indifferent disease states,
which further warrants additional studies to validate the role and
mechanism of fractalkine/CX3CL1 mediated pathogenesis in SS.
SYSTEMIC LUPUS ERYTHEMATOSUS
Systemic lupus erythematosus (SLE) is an autoimmune disease
characterized by multiorgan damage with inﬁltration and seques-
tration of various immune cells (Umehara et al., 2006). Yajima
et al. (2005) reported that serum fractalkine/CX3CL1 levels were
signiﬁcantly more elevated in patients with SLE than in the
healthy controls. Both fractalkine/CX3CL1 expression and CD16
accumulation are markedly elevated in patients with prolifera-
tive lupus nephritis (Nakatani et al., 2010). In another study, a
fractalkine/CX3CL1 antagonistwas administered toMRL/lpr mice
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before the onset or during the early stages of lupus nephritis.
Results from the study showed that the mice exhibited signif-
icantly reduced glomerular hypercellularity, glomerulosclerosis,
crescent formation, and vasculitis when compared with control
mice (Inoue et al., 2005). SLE patients have a predisposition to
develop cardiovascular diseases. In SLE, the incidence of myocar-
dial infarction is ﬁve times higher than that of the general popu-
lation and as much as 50 times higher in young women (Cypiene
et al., 2010). In a clinical study of patients with SLE, soluble
fractalkine/CX3CL1 fromserumsamplesweremeasured and com-
pared to patients with other autoimmune diseases. The serum
levels of soluble fractalkine in SLE patients were higher than
patients with RA and SS (Sato et al., 2006). Recently, Li et al.
(2010b) has proposed CX3CR1 as an indicator in clinical surveil-
lance of SLE based on mRNA analysis from RT-PCR on peripheral
blood mononuclear cells (PBMCs) of SLE patients. These stud-
ies suggest that a fractalkine/CX3CL1 antagonist may delay the
progression of human SLE.
SCLERODERMA
Scleroderma (systemic sclerosis) is a chronic systemic autoim-
mune disease characterized by ﬁbrosis and vascular alterations pri-
marily of the skin. Scleroderma has two major forms: limited scle-
roderma, involving cutaneous manifestations mainly of the hands,
arm, and face, and diffuse systemic scleroderma, affecting large areas
of the skin as well as internal one or more internal organs such as
the kidneys, esophagus,heart, and lungs. Patientswith scleroderma
may develop other rheumatic diseases such as SLE, RA, and SS as
well as pulmonary arterial hypertension (Gabrielli et al., 2009).
Enhanced expression of fractalkine/CX3CL1 has been shown in
the affected skin and lung tissues of patientswith cutaneous sclero-
derma (Hasegawa et al.,2005). This increased expression augments
the recruitment of mononuclear cells into the affected tissue lead-
ing to inﬂammation (Hasegawa et al., 2005). Polymorphisms of
CX3CR1 promote pathogenesis; where the 429I and 480M alleles
are signiﬁcantly increased in sclerodermapatientswith pulmonary
arterial hypertension. Increased susceptibility to scleroderma is
associated with the 249II CX3CR1 polymorphism (Marasini
et al., 2005). Intravenous administration of prostaglandin E1 was
reported to down-regulate serum fractalkine/CX3CL1 levels as
well as CD11a and CD49d integrin expression on peripheral blood
lymphocytes, adding another potential mechanism to the efﬁ-
cacy of prostaglandin E1 in scleroderma associated pulmonary
hypertension (Sicinska et al., 2008).
SYSTEMIC INFLAMMATORY CONDITIONS
Fractalkine/CX3CL1 has been shown to play an important role
in systemic inﬂammation, which also contributes as a secondary
complication of rheumatic diseases (Table 1). Possible mecha-
nisms for the role of fractalkine/CX3CL1 in coronary plaque
rupture include an increase in CX3CR1-expressing monocytes or
macrophage activation byCX3CR1-expressing T lymphocytes and
NK cells at the site of inﬂammation (Ikejima et al., 2010). Studies
are ﬁnding evidence that fractalkine/CX3CL1 plays an impor-
tant role in atherosclerosis. Fractalkine/CX3CL1 expression is
upregulated in atherosclerotic lesions of apolipoprotein E (apoE)-
deﬁcient mice, and crossing CX3CR1−/− with apoE−/− decreases
atherosclerotic lesion formation with reduced macrophage accu-
mulation (Combadiere et al., 2003; Lesnik et al., 2003; Umehara
et al., 2004). Hence, addressing a therapeutic need of regulat-
ing CX3CL1–CX3CR1 duo mediated atherosclerosis may have a
signiﬁcant impact on the treatment of RA or SLE in terms of
minimizing the detrimental vascular remodeling as one of these
disease co-morbidities. In a study by Liuzzo et al. (2001) showed
that IFN-γ derived from stimulated T lymphocytes activated
monocytes obtained from the patients with unstable angina pec-
toris. These ﬁndings suggest that increased CX3CR1-expressing
monocytes, T lymphocytes, and NK cells may result in a burst
of macrophage activation, which could lead to plaque rupture
(Ikejima et al., 2010). Fractalkine/CX3CL1 also plays a role in
inﬂammatory cardiomyopathy, in which its upregulation affects
the functional potential of PBMCs in inducing a cardiodepres-
sive effect on heart tissue (Escher et al., 2011). Through in vitro
and in vivo models, fractalkine/CX3CL1 has also been shown to
induce angiogenesis in HepG2 cells (Li et al., 2010a). This suggests
that fractalkine/CX3CL1 may inﬂuence hepatic biology during
the inﬂammatory phase of rheumatic conditions such as RA or
SLE and contribute to amplifying systemic inﬂammation in the
established phase of the disease through the enhanced synthesis or
expression of acute phase reactive proteins such as C-reactive pro-
tein, ﬁbrinogen, or serum amyloid A. Further studies are awaited
to pinpoint the exact role of fractalkine/CX3CL1 in chronic vas-
cular diseases, which may shed some light on its mechanism of
action and possible contribution in cardiovascular co-morbidities
in the rheumatic population.
FRACTALKINE/CX3CL1 AS A THERAPEUTIC TARGET
Limited understanding of the exact mechanism of fractalkine/
CX3CL1 synthesis and proteolytic shedding and the signaling
pathways that mediate the downstream events initiated by the
fractalkine/CX3CL1–CX3CR1 duo has been a major hurdle in the
path of designing therapeutic molecules targeting this chemokine
selectively. However, this has not dampened the enthusiasm of
pharmacologists and medicinal chemists as some of the alter-
native therapeutic strategies such as the inhibition of enzymes
that process soluble fractalkine/CX3CL1 or CX3CR1 antago-
nists have been tried and tested with some promising results
(Wiener et al., 2010). Furthermore, elucidation of the structure
of fractalkine/CX3CL1 has made it possible to develop analogs
to inhibit CX3CR1. In this regard, Inoue et al. (2005) devel-
oped fractalkine/CX3CL1 analogs by truncating four N-terminal
amino acids, inhibiting the expression in rodent glomerular
endothelial cells. Another therapeutic study has proposed using
fractalkine/CX3CL1 antagonists with IL-4 antagonists in treat-
ing HIV-1 patients to limit the pathogenic potential of the virus
(Becker, 2007).
Testing of the existing therapies used for inﬂammatory dis-
eases in the suppression of fractalkine/CX3CL1 expression and
release has gained some momentum (see Table 2). For example,
in vitro testing of aspirin showed that inhibition of TNF-α induced
fractalkine/CX3CL1 expression in HUVECs through the regula-
tion of the NF-κB pathway (Jiang et al., 2009). Along those lines,
several other studies have shown that TNF-α inhibitors decrease
fractalkine/CX3CL1 expression (Feldmann and Maini, 2001; Scott
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Table 1 | Summary of some basic and clinical human studies on the role of fractalkine/CX3CL1 in rheumatic diseases.
Disease Description Model Citation
RA Expression in macrophages, ﬁbroblasts, endothelial, and
dendritic cells in RA ST
RA ST Denes et al. (2008)
Elevated levels of soluble fractalkine/CX3CL1 in RA SF RA SF Denes et al. (2008)
Fractalkine/CX3CL1 levels were signiﬁcantly elevated in RA
SF compared to the SF from osteoarthritis patients
RA and OA patients Denes et al. (2008)
Fractalkine/CX3CL1 mRNA expression signiﬁcantly
increased byTNF-a stimulation
HUVECs Garcia et al. (2000)
IFN-γ andTNF-α synergistically induce fractalkine/CX3CL1
expression
HUVECs, astrocytes,
RA synovial ﬁbroblasts
Hasegawa et al. (2005), Hund-
hausen et al. (2003, 2007)
Threefold increase in CX3CR1 surface expression on CD8+ T
cells compared to healthy subjects
RA patients Koch (2005)
RA SF depleted of fractalkine/CX3CL1 exhibits a lower
angiogenic effect as compared to control SF
RA patients Lee et al. (2009)
Fractalkine/CX3CL1 is signiﬁcantly expressed in rheumatoid
vasculitis patients where expression levels correlate to
severity of vasculitis
RA patients with
rheumatoid vasculitis
Li et al. (2010a)
SS Serum levels are ∼1.8-fold higher than RA patient and
∼3.6-fold higher than healthy patients
S5 patients Matsumiya et al. (2010)
SLE Soluble serum fractalkine/CX3CL1 levels are higher in
patients with SLE than RA and SS
SLE patients Matsumiya et al. (2010)
Serum expression of fractal kine/CX3CL1 was signiﬁcantly
higher in SLE patients compared to healthy controls
SLE patients Moon et al. (2006)
Li et al. (2010a) proposed CX3CR1 as an indicator in clinical
surveillance of SLE based on mRNA analysis
PMBCs of SLE
patients
Nanki et al. (2004)
Scleroderma Enhanced fractalkine/CX3CL1 expression in affected skin
and lung tissues of patients with cutaneous scleroderma
Scleroderma patients Odai et al. (2009)
429I and 480M polymorphisms are signiﬁcantly increased in
scleroderma patients with pulmonary arterial hypertension
Scleroderma patients Okamoto et al. (1997)
Increased susceptibility to scleroderma is associated with
the 249II CX3CRI polymorphism
Scleroderma patients Okamoto et al. (1997)
Systemic inﬂammation Fractalkine/CX3CL1 induces a cardiodepressive effect on
PBMCs in inﬂammatory cardiomyopathy (CMi) patients
PBMCs in CMi
patients
Sato et al. (2006)
Through in vivo and in vitro models, fractalkine/CX3CL1
induces angiogenesis in HepG2 cells
HepG2 cells Sawai et al. (2007)
RA, rheumatoid arthritis; SS, Sjögren’s syndrome; OA, osteoarthritis; SLE, systemic lupus erythematosus; CVD, cardiovascular disease; SF, synovial ﬂuid; PBMCs,
peripheral blood mononuclear cells; AIA, adjuvant induced arthritis; CIA, collagen induced Arthritis; NOD, non-obese diabetic; CMI, cardiomyopathy; UAP, unstable
angina pectoris; ApoE, apolipoprotein E; HUVECs, human umbilical vascular endothelial cells.
and Kingsley, 2006; Odai et al., 2009). However, TNF antago-
nists such as inﬂiximab, etanercept, and adalimumab have only
limited efﬁcacy against conditions related to systemic vascular
pathology, which warrants further correlative studies (Aries et al.,
2007; Lin et al., 2008). On a positive note, a recent study showed
that themimetic peptideApo-A1 regulates TNF-α-inducedmono-
cyte chemotaxis partly by inhibiting fractalkine/CX3CL1 synthesis
in human coronary artery endothelial cells (Di Bartolo et al.,
2011).
Similarly, baclofen (a GABAB receptor agonist) was shown to
induce heterologous desensitization of CX3CR1 as well as other
chemokine receptors (Duthey et al., 2010). Complementary and
alternative medicine (CAM) approaches that have shown beneﬁt
in rheumatic diseases have been tested for their efﬁcacy in regulat-
ing fractalkine/CX3CL1 production (Chen et al., 2011; Pirvulescu
et al., 2011; Wang et al., 2011). A recent example of this includes
epigallocatechin-3-gallate (EGCG), a potent anti-inﬂammatory
compound found in green tea known to inhibit experimen-
tal arthritis, which has been found to decrease TNF-α induced
fractalkine/CX3CL1 expression in HUVECs through NF-κB path-
way regulation (Ahmed et al., 2008; Lee et al., 2009). Another
study by Moon et al. (2006) also found suppression of TNF-α
induced fractalkine/CX3CL1 expression in HUVECs by resvera-
trol, a polyphenolic compound present in grapes and red wine
with anti-inﬂammatory, antioxidant, and antitumor properties.
Wan and Evans (2010) investigated the effects of rosiglitazone
(PPARγ agonist) on fractalkine/CX3CL1 expression. The acti-
vation of PPARγ by rosiglitazone in macrophages and HUVECs
repressed the transcription of the fractalkine/CX3CL1 and nuclear
export respectively, suggesting that PPARγ activationmay suppress
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Table 2 | Potential therapeutic strategies to regulate fractalkine/CX3CL1 in rheumatic diseases.
Therapeutic agent Pharmacologic action Physiologic response Model Citation
Resveratrol Anti-inﬂammatory, antioxidant,
and antitumor properties
Suppressed
fractalkine/CX3CL1 levels
HUVECs Garcia et al. (2000)
Anti-fractalkine/CX3CL1
monoclonal antibody
Inhibition of fractalkine/CX3CL1
and CX3CR1 binding
Signiﬁcantly reduced
clinical arthritis score
DBA1/J mice Lanier et al. (1997)
Glucocorticoids,
methotrexate
Immunosuppression,
cytotoxic/chemotherapeutic,
resp.
Decreased soluble levels
in serum
RA patients with RV Li et al. (2010a)
Fractalkine/CX3CL1
antagonist
Blockade of fractalkine/CX3Cl
and CX3CR1 binding
Lowered lupus nephritis
symptoms
MRL/lpr mice Nakayama et al. (2010)
Prostaglandin E1 Potent vasodilator Down-regulate serum
fractalkine/CX3CL1 levels
Scleroderma patients Paludan (2000)
Aspirin Cyclooxygenase 1/2 (COX 1/2)
inhibitor
Inhibition of
fractalkine/CX3CL1
expression by NF-κB
regulation
HUVECs Scott and Kingsley (2006)
TNF antagonist
(inﬂiximab, etanercept,
adalimumab)
Binds to TNF-α, preventing
receptor activation
Decrease
fractalkine/CX3CL1
expression
RA patients Sicinska et al. (2008), Tanaka
et al. (1993), Tsubota et al.
(2009)
Baclofen GABAB receptor agonist Heterologous
desensitization of CX3CR1
Human PBMCs Umehara et al. (2006)
Epigallocatechin-3-gallate
(EGCG)
Anti-inﬂammatory compound Lowered
fractalkine/CX3CL1
expression by NF-κB
regulation
HUVECs Wang et al. (2011),Wiener et al.
(2010)
Rosiglitazone PPARγ receptor agonist Repressed transcription
and nuclear export of
fractalkine/CX3CL1
Macrophages/HUVECs Wildenberg et al. (2008)
Iota-Carrageenan Antiviral nasal spray Reduction of CX3CL1
expression in nasal lavage
Common cold patients Yajima et al. (2005)
fractalkine/CX3CL1 signaling (Wan and Evans, 2010). Eccles et al.
(2010) has tested an antiviral nasal spray called Iota-Carrageenan,
which is derived from seaweed and is characterized by the US Food
and Drug Administration as “generally regarded as safe” (GRAS).
In patients with symptoms of the common cold treatment
with Iota-Carrageenan reduced fractalkine/CX3CL1 expression by
roughly 45–50% in nasal lavage.
CONCLUSION
Fractalkine/CX3CL1 is a unique chemokine with chemotactic
activity for monocytes, NK cells, and T cells. It also acts as an
adhesion molecule for leukocytes. Emerging evidence of its active
involvement in many rheumatic diseases such as RA, SS, SLE, and
scleroderma as well as other diseases related to vascular inﬂam-
mation has made fractalkine/CX3CL1 an attractive therapeutic
target. In the last few years, therapeutic approaches, both direct
(CX3CR1 antagonist or CX3CL1 analogs) and indirect (signal-
ing inhibitors, TACE activity inhibitors, or immunosuppressive
drugs) have been triedwith some success.However, a better under-
standing of the cell-speciﬁc activation, synthesis, and shedding of
fractalkine/CX3CL1 and regulated manipulation of such steps will
further assist pharmacologists to develop highly targeted ther-
apeutic approaches to limit its pathological role in rheumatic
diseases and other cardiovascular diseases.
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